Dezhan Health has released its 2026 semi-annual performance forecast, expecting a net loss attributable to shareholders of 38 million to 75 million yuan for the first half, compared with a loss of 42.9265 million yuan in the same period last year. The company stated that the loss is mainly due to the continued deepening of its business structure integrating pharmaceuticals, medical services, and health, increased investment in innovative research and development, and the impact of volume-based procurement policies on revenue.
Dezhan HealthCare Co LtdExpects first-half net loss of 38-75 million yuan, worse than last year's loss of 42.9 million yuan.